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The study of adenovirus could greatly benefit from diverse methods of virus detection. Recently, it has been demonstrated that carboxy-
terminal EGFP fusions of adenovirus core proteins Mu, V, and VII properly localize to the nucleus and display novel function in the cell. Based on
these observations, we hypothesized that the core proteins may serve as targets for labeling the adenovirus core with fluorescent proteins. To this
end, we constructed various chimeric expression vectors with fusion core genes (Mu-EGFP, V-EGFP, preVII-EGFP, and matVII-EGFP) while
maintaining expression of the native proteins. Expression of the fusion core proteins was suboptimal using E1 expression vectors with both
conventional CMVand modified (with adenovirus tripartite leader sequence) CMV5 promoters, resulting in non-labeled viral particles. However,
robust expression equivalent to the native protein was observed when the fusion genes were placed in the deleted E3 region. The efficient Ad-wt-
E3-V-EGFP and Ad-wt-E3-preVII-EGFP expression vectors were labeled allowing visualization of purified virus and tracking of the viral core
during early infection. The vectors maintained their viral function, including viral DNA replication, viral DNA encapsidation, cytopathic effect,
and thermostability. Core labeling offers a means to track the adenovirus core in vector targeting studies as well as basic adenovirus virology.
© 2006 Elsevier Inc. All rights reserved.Keywords: Adenovirus; Vector; Gene therapy; Core proteins; Mu; V; VII; EGFP; Fluorescent labelingIntroduction
There are 51 identified human adenovirus serotypes of which
some manifest clinical relevance while others have been applied
as gene delivery vectors (Russell, 2000). The study of
adenoviruses with regard to virology, pathology, and gene
therapy has greatly benefited from various detection methods,
including quantitative and localizing techniques which can
probe for viral DNA, RNA, and protein at the molecular level.
In the context of adenoviral vector design, reporter gene
expression has likewise played a vital role in the evaluation of
vector transduction and transcriptional control both in vitro and
in vivo. However, full understanding of the key steps of
adenovirus host–cell interaction, cell entry, genome delivery,
replication, and progeny dissemination requires detection
modalities which can follow viral components and particles at⁎ Corresponding author. Fax: +1 205 975 7476.
E-mail address: curiel@uab.edu (D.T. Curiel).
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doi:10.1016/j.virol.2006.03.042the microscopic level, preferably in real time. Indeed, methods
founded on this rationale have demonstrated the power of
tracking individual adenoviral particles intracellularly. Studies
have applied ex vivo, non-specific chemical conjugation of the
adenovirus capsid with synthetic fluorophores (e.g., fluorescein
isothiocyanate, Texas Red, carbocyanine 3) to evaluate viral
entry (Leopold et al., 1998; Nakano and Greber, 2000), examine
the effect of fiber modification on intracellular trafficking
(Bernt et al., 2003; Miyazawa et al., 1999), and show the
dynein-dependent nature of adenovirus interaction with micro-
tubules (Kelkar et al., 2004).
Recently, we and others successfully developed in vivo
labeling of adenovirus with the enhanced green fluorescent
protein (EGFP) fused to the minor capsid protein IX (Le et al.,
2004; Meulenbroek et al., 2004). These studies illustrated
specific and homogeneous capsid labeling of adenovirus by
genetic means to yield fluorescent adenoviruses possessing full
virus function and utility in the tracking of infection as well as
the detection of viral biodistribution. The ability to track the
Fig. 1. Schematic of vectors. Nomenclature and configuration of expression
vectors where X represents Mu-EGFP, V-EGFP, preVII-EGFP, or matVII-EGFP.
The employed expression strategies include transcription via the typical CMV
promoter, a modified CMV promoter containing the adenovirus tripartite leader
sequence (CMV5), and the adenovirus major late promoter (by virtue of
transgene cassette insertion into the deleted E3 region).
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potential detection strategy distinct from capsid labeling and
would be operative in following adenovirus genome delivery,
an imperative step in both natural infection and gene transfer.
Previously in vivo genome labeling was demonstrated using a
tetR-EGFP fusion protein which binds to tetO repeats
incorporated into the adenovirus genome (Glotzer et al.,
2001). Although the labeling was feasible, analysis by the
authors showed that the tandem tetO repeat sequence was prone
to deletion by recombination. Furthermore, the technique was
based on an exogenous, nonviral fusion protein tetR-EGFP
label expressed in a producer cell line. It would be ideal and
perhaps more efficient if in vivo labeling of the adenovirus
genome could be accomplished with an endogenous viral
protein expressed from the vector itself without the need for a
producer cell line.
Adenoviruses are nonenveloped, double-stranded DNA
viruses with an icosahedral structure constructed from an
array of twelve different proteins. Their approximate 36-kb
genome is covalently bound to two terminal proteins and further
organized through non-covalent association with the three core
proteins Mu, V, and VII. All three core proteins are translated
from the common L2 transcript under the control of the major
late promoter (Alestrom et al., 1984). Protein VII (pVII) is the
major core protein contributing over 800 copies per virion
(Lehmberg et al., 1999). Expressed as a 174-amino-acid
precursor from which a 24-amino-acid N-terminus is cleaved
(Sung et al., 1983), its functional and sequence homology to
histone H3 (Cai and Weber, 1993; Lee et al., 2003) indicates
that pVII acts as a histone-like center around which viral DNA
is wrapped to form nucleosome structures (Chatterjee et al.,
1986; Mirza and Weber, 1982). Protein V (pV) is speculated to
serve as a bridge between the genome core and the capsid
through association with proteins Mu, VI, and VII as well as the
viral DNA (Chatterjee et al., 1985; Matthews and Russell, 1998;
Vayda and Flint, 1987). There are more than 150 copies of the
minor core protein V per virion which binds non-specifically to
the viral DNA (Chatterjee et al., 1985, 1986; Lehmberg et al.,
1999). Mu or protein X matures into a 19-amino-acid final form
(Mu) after both amino- and carboxy-terminal cleavage of the 79
amino acid precursor (preMu) by the adenovirus encoded
protease. The copy number per virion of Mu is not known
(Chatterjee et al., 1985). Because of its ability to precipitate
negatively charged DNA in vitro via its nine positively charged
arginine residues, it has been postulated to play a role in viral
DNA condensation in the core (Anderson et al., 1989).
Recent intracellular localization and functional studies of
Mu, pV, and pVII were performed with carboxy-terminal fusion
of EGFP to the native proteins (Lee et al., 2003, 2004;
Matthews, 2001). Our attention was drawn to three established
observations from these reports: (i) nuclear localization of the
fusion core proteins was conserved, (ii) the fusion core proteins
demonstrated some function in the cell, and (iii) pVand pVII are
found at ample copy numbers per virion. Based on these
findings, we hypothesized that the core proteins may serve as
targets for labeling of adenoviruses with fluorescent proteins.
Herein, we describe the genetic labeling of the adenovirus corethrough the use of a chimeric expression system of both the
native and fluorescent fusion core proteins. Adenovirus core
labeling offers a unique way to follow the adenovirus core with
potential for studying adenovirus infection and biology as well
as tracking adenoviral vectors in gene therapy applications.
Results
Fluorescent fusion core protein expression and localization
We chose a chimeric system to generate recombinant
adenoviruses expressing control EGFP and the fluorescent
fusion core proteins: Mu-EGFP, pV-EGFP, preVII-EGFP, and
matVII-EGFP. PreMu-EGFP was not chosen as a candidate for
labeling because it has been shown to block late adenovirus
gene expression when expressed concomitantly with adenovi-
rus infection (Lee et al., 2004). In the chimeric expression
system, both the native, unmodified core protein and the fusion
counterpart were expressed from the same vector. We initially
applied the AdEasy system to construct E1 expression vectors
under the control of the constitutive cytomegalovirus (CMV)
promoter (Fig. 1). After transient transfection of the final
genomes into 911 cells, rescue of all viruses was successful.
Expression and localization of the fusion core proteins from the
E1 expression vectors were verified 24 h postinfection in A549
cells. Fluorescence microscopy revealed expression of all
fusion core proteins (Fig. 2). Control EGFP localized diffusely
throughout the cytoplasm and nucleus, while all four fusion
core proteins demonstrated strong nuclear localization. Mu-
EGFP showed diffuse cytoplasmic signal along with nucleo-
plasmic and what appears to be nucleolar targeting. Protein V-
EGFP, like Mu-EGFP, localized to both the nucleoplasm and the
nucleoli; however, little protein was found in the cytoplasm.
preVII-EGFP distributed exclusively to the nucleus with signals
detected in the nucleoplasm, the nucleoli, and areas where the
DNA Hoechst stain associated with the cellular chromosomes.
matVII-EGFP colocalized almost entirely with the host cell
DNA, while some of the protein was also visualized in the
nucleoplasm. The image of matVII-EGFP was nearly indistin-
guishable from the picture captured for Hoechst stain of the
same field. In 911 cells in which the viruses actively replicated,
Fig. 2. Fluorescent core fusion protein expression and localization. A549 cells were infected with nonreplicative E1-CMVadenovirus vectors expressing the indicated
genes. The cells were fixed and stained for nuclear DNA 24 h postinfection followed by visualization of the fluorescent proteins by epifluorescence microscopy.
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as that seen in A549 cells (data not shown). These results agree
with published data obtained from plasmid-derived transient
expression of the same fusion core proteins (Lee et al., 2003,
2004; Matthews, 2001).
Fluorescence of E1-CMV expression vector viral particles
After validating proper expression and intracellular traffick-
ing of the fusion core proteins from the E1-CMV expression
vectors, we analyzed the fluorescence of purified virus fractions
collected from the CsCl gradient after two rounds of
ultracentrifugation. During purification, both the mature and
immature viral bands were retained. In our previous study
involving fluorescent capsid-labeled adenovirus (Le et al.,
2004), this procedure was established as a useful assay to detect
fluorescence signal colocalizing with the purified viral bands.
Each gradient fraction was quantitated for EGFP fluorescence
and viral DNA content (optical absorbance at 260 nm, data not
shown). The results were discouraging in that only minor
fluorescent peaks were detected for the bottom mature virus
band of Ad-E1-CMV-preVII-EGFP and the top immature virus
band of Ad-E1-CMV-V-EGFP (data not shown), in contrast to
our pIX-EGFP-labeled adenovirus which showed strong peaks
(Le et al., 2004). We corroborated these data with fluorescence
microscopy of samples from the bottom and top bands for each
virus and found only occasional fluorescent particles, the
number of which was disproportionately lower than the numberof viral particles predicted by absorbance measurements at
260 nm (data not shown).
Western blot analysis of Ad-E1-CMV-V-EGFP purified virus
and infected cells
With available anti-sera against the adenovirus pV, Western
blot analysis was performed to detect pV-EGFP expression and
incorporation into viral particles on a more molecular level.
Purified virions collected from the top and bottom bands of
control Ad-E1-CMV-GFP and Ad-E1-CMV-V-EGFP were
examined. Although fluorometry analysis revealed a flat
response throughout the gradient, GFP protein was unexpect-
edly found in the mature band of Ad-E1-CMV-GFP in contrast
to our previous study (Le et al., 2004) (Fig. 3A, left panel, lane
1). Understandably, more GFP was detected in the immature
band where it is expected to migrate along with unassociated
cellular debris and proteins in the gradient (Fig. 3A, left panel,
lane 2). A low level of pV-EGFP was detected in the bottom
band, whereas significantly more was found in the top band
(Fig. 3A, left panel, lanes 3 and 4, respectively), matching the
results obtained in the fluorometry experiment. Probing with the
pV anti-sera confirmed the findings obtained with the GFP
antibody; however, it also showed that Ad-E1-CMV-V-EGFP
virions contained substantially less of the fusion core protein
than the native pV (Fig. 3A, right panel, lanes 3 and 4),
suggesting inefficient incorporation of the fusion core pV-EGFP
relative to the native version. We further analyzed the
Fig. 3. Western blot analysis of Ad-E1-CMV-V-EGFP purified virus and cells
infected with various expression vectors. (A) Purified viruses (8 μg protein in
each sample) and infected cell lysates (4 μg protein each sample) were subjected
to SDS-PAGE and blotted with GFP and pVantibodies. Lanes (1) Ad-E1-CMV-
EGFP bottom band, (2) Ad-E1-CMV-EGFP top band, (3) Ad-E1-CMV-V-EGFP
bottom band, (4) Ad-E1-CMV-V-EGFP top band, (5) Ad-E1-CMV-GFP
infected 911 cells, and (6) Ad-E1-CMV-V-EGFP infected 911 cells. (B) Protein
lysates (10 μg) from 911 cells infected with the various V-EGFP expression
vectors were subjected to SDS-PAGE and blotted with GFP and pV antibodies.
Lanes (1) Ad-E1-CMV-EGFP, (2) Ad-E1-CMV-V-EGFP, (3) Ad-E1-CMV5-V-
EGFP, and (4) Ad-wt-E3-V-EGFP. (C) Purified core-labeled viral particles
(1.5 × 1010) were subjected to SDS-PAGE and then silver-stained. Lanes: (L)
protein ladder, (1) Ad-wt-E3-EGFP, (2) Ad-wt-E3-V-EGFP, and (3) Ad-wt-E3-
preVII-EGFP. The numbers on the left side indicate the molecular weight of the
protein ladder (kDa). The labels on the right highlight the major Ad structural
proteins visible on the SDS-PAGE.
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EGFP infection. Western blot analysis revealed that intracellular
expression of the fusion core protein relative to the native
protein paralleled the observations made above with the purified
virus. Considerably lower expression of pV-EGFP was noted
relative to natural pV (Fig. 3A, right panel, lane 6). These data
indicate that the inefficient incorporation of pV-EGFP into
virions may be due to the unfavorable expression of pV-EGFP
in comparison to native pV, although assembly defect due to
EGFP fusion could also be possible.Enhanced expression of pV-EGFP from the E3 region
As a result of the poor expression achieved with the E1-
CMV vectors, we explored the possibility of increasing the
fusion core protein expression relative to the native protein by
using two approaches. The first strategy involved the use of the
CMV5 promoter (Qbiogene, Fig. 1) to drive expression of the
fusion core proteins from the E1-deleted region. This modified
promoter features the adenovirus tripartite leader sequence
downstream of the CMV promoter which has been previously
shown to enhance transgene expression (Sheay et al., 1993).
Our attempt to generate E1-CMV5 fusion core protein
expression viruses unfortunately resulted in unsuccessful rescue
of all candidate vectors (Ad-E1-CMV5-Mu-EGFP, Ad-E1-
CMV5-preVII-EGFP, and Ad-E1-CMV5-matVII-EGFP) ex-
cept the control Ad-E1-CMV5-EGFP and Ad-E1-CMV5-V-
EGFP. The second strategy to generate vectors with enhanced
expression exploited the deleted E3 region of the adenovirus
genome to express transgenes (Fig. 1). Previous reports have
demonstrated that efficient expression late in infection could be
attained by using this locale for transgene insertion, likely due
to transcription from the major late promoter, polyadenylation,
and splicing with the tripartite leader sequence (Hawkins and
Hermiston, 2001a,b; Hawkins et al., 2001; Mittal et al., 1993).
Contrary to the results obtained with the E1-CMV5 expression
vectors, we were successful in rescuing most of the E3
expression vectors (Ad-wt-E3-EGFP, Ad-wt-E3-Mu-EGFP,
and Ad-wt-E3-V-EGFP) except Ad-wt-E3-matVII-EGFP.
To verify enhanced expression of the fusion core proteins was
indeed achieved using the E1-CMV5 and E3 chimeric expression
strategies, Western blot analysis was performed with cell lysates
from 911 cells infected with 1 CPEU/cell (cyptopathic effect
unit) of the various vectors 24 h postinfection. Representative
analysis was performed with the V-EGFP vectors. Although we
observed strong expression of EGFP from the control Ad-E1-
CMV-EGFP vector (Fig. 3B, left panel, lane 1), the expression of
V-EGFP driven by the E1-CMVand E1-CMV5 vectors was quite
low when probed with both the EGFP and pV antibodies (Fig.
3B, left and right panels, lanes 2 and 3, respectively). In our
hands, the CMV5 did not provide improved transgene expression
over the unmodified CMV promoter, particularly with V-EGFP
as the transgene. However, pV-EGFP expression from the
deleted E3 region was detected at a significant level (Fig. 3B, left
and right panels, lane 4) comparable to the amount of native pV
(Fig. 3B, right panel, lane 4).
SDS-PAGE was used to compare the major structural protein
composition of purified Ad-wt-E3-V-EGFP and Ad-wt-E3-
preVII-EGFP to that of the control vector Ad-wt-E3-EGFP. Silver
staining revealed no gross differences in the protein compositions
of these three viruses. Note that bands corresponding to pV-EGFP
and pVII-EGFP were not apparent on SDS-PAGE (Fig. 3C).
Fluorescence of Ad-E1-CMV5-V-EGFP and E3 fusion core
protein expression vectors
The fluorometry assay described above was repeated with
CsCl gradient fractions of Ad-E1-CMV5-V-EGFP (the only
295L.P. Le et al. / Virology 351 (2006) 291–302rescued core protein E1-CMV5 vector) and the E3 expression
viruses. As predicted by the Western blot analysis, no
fluorescent peaks in the bottom and top viral bands were
detected for Ad-E1-CMV5-V-EGFP like the included controlFig. 5. Visualization of Ad-wt-E3-V-EGFP and Ad-wt-E3-preVII-EGFP
particles. Purified Ad-wt-E3-V-EGFP (A) and Ad-wt-E3-preVII-EGFP (B)
were prepared on slides with coverslips and imaged with epifluorescence
microscopy.vector Ad-E1-CMV5-EGFP (Fig. 4, middle panel). Ad-wt-E3-
Mu-EGFP revealed very small peaks for both the mature virus
and empty particle bands (Fig. 4, top panel). Both Ad-wt-E3-V-
EGFP and Ad-wt-E3-preVII-EGFP displayed strong fluorescent
peaks for the bottom bands and a couple of minor peaks above
the mature particle band (Fig. 4, middle and bottom panels,
respectively). All major fluorescent peaks in the bottom bands of
Ad-wt-E3-V-EGFP and Ad-wt-E3-preVII-EGFP coincided with
viral DNA peaks measured by absorbance at 260 nm (Fig. 4,
middle and bottom panels, respectively). It is interesting to note
that both Ad-wt-E3-V-EGFP and Ad-wt-E3-preVII-EGFP did
not show major peaks in the top band (empty capsids with little
or no viral DNA), whereas our previous capsid-labeled Ad-IX-
EGFP virus demonstrated a strong fluorescent peak in the top
band comparable to the bottom band (Le et al., 2004). This
observation may be unique to the core-labeled vectors whichFig. 4. Analysis of fusion core protein viral gradients with improved
expression. Fusion core protein vectors with enhanced expression were
purified and fractionated to determine fluorescence of CsCl gradient fractions.
For all panels, unlabeled Ad-E1-CMV5-EGFP was included as a control
(–□–). Ad-E1-CMV5-X (–△–) and Ad-wt-E3-X (–○–) are shown where X
is the indicated fusion protein at the top of the panel. Note that Ad-E1-CMV5-
Mu-EGFP, Ad-E1-CMV5-preVII-EGFP, Ad-E1-CMV5-matVII-EGFP, and
Ad-wt-E3-matVII-EGFP could not be rescued for analysis. For Ad-wt-E3-V-
EGFP and Ad-wt-E3-preVII-EGFP, viral DNA content was also analyzed for
the respective fractions (–♢–).
296 L.P. Le et al. / Virology 351 (2006) 291–302contain fusion core proteins with the propensity to interact with
viral DNA as opposed to the capsid-labeled vector.
Visualization of Ad-wt-E3-V-EGFP and
Ad-wt-E3-preVII-EGFP fluorescent particles
After confirming fluorescent labeling of the E3 fusion core
protein vectors with the fractionation assay, the purified viral
particles were examined under fluorescence microscopy.
Abundant Ad-wt-E3-V-EGFP and Ad-wt-E3-preVII-EGFP
fluorescent particles could be visualized (Figs. 5A and B,
respectively) while Ad-wt-E3-Mu-EGFP virions could not be
detected (data not shown), suggesting the poor labeling
efficiency of this vector.Fig. 6. Tracking of core-labeled virus infection. HeLa cells were infected with Ad-w
preVII-EGFP (right column) at 37 °C and then imaged at 1 h (upper 2 rows) and 3 h (b
EGFP fluorescence and some background autofluorescence; blue indicates nucl
arrows = fluorescent viral particles in the cytoplasm. Orange arrows = fluorescent vir
are merged color images overlaid on top of a phase contrast picture of the cells to sTracking early infection with core-labeled adenovirus
To demonstrate the utility of our core labeling technique, we
tracked the fate of the pV-EGFP and preVII-EGFP-labeled
viruses during early infection of HeLa cells. While no
fluorescent signal resembling viral particles were observed
with the control Ad-wt-E3-EGFP virus, numerous fluorescent
particles could be visualized in the cytoplasm (white arrows) and
nuclei (orange arrows) of cells infected with Ad-wt-E3-V-EGFP
and Ad-wt-E3-preVII-EGFP for 1 h at 37 °C (Fig. 6, top two
rows). After 3 h of infection at 37 °C, some residual Ad-wt-E3-
V-EGFP fluorescent particles were detected in the cytoplasm
while very few or no fluorescent particles were seen in the
nucleus. In contrast, many Ad-wt-E3-preVII-EGFP fluorescentt-E3-EGFP (left column), Ad-wt-E3-V-EGFP (middle column), and Ad-wt-E3-
ottom 2 rows) postinfection using epifluorescence microscopy. Green represents
ear DNA; and red, yellow, and brown represent background signal. White
al particles in the nucleus. Note that the bottom row pictures for each time period
how morphology.
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few were found in the cytoplasm. Although some cells had
started to weakly express pV-EGFP or preVII-EGFP at 3 h after
infection, strong EGFP expression was noted in cells infected
with the control Ad-wt-E3-EGFP virus (Fig. 6, bottom two
rows). By 6 h after infection, all cells strongly expressed EGFP,
pV-EGFP, or preVII-EGFP with localization patterns similar to
those shown in Fig. 2. The high level of newly synthesized
fluorescent signal interfered with detection of the input
fluorescent particles at 6 h after infection (data not shown).
DNA packaging analysis of core-labeled adenoviruses
The core proteins play essential roles in packaging of the
viral genome inside the capsid. We tested whether our chimeric
system of expressing the fusion core proteins in competition
with the endogenous proteins would affect viral DNA
packaging. For this analysis, we infected 911 cells with the
labeled vectors Ad-wt-E3-V-EGFP and Ad-wt-E3-preVII-
EGFP along with the control Ad-wt-E3-EGFP (1 CPEU/cell
of each virus). Total intracellular viral DNA and encapsidated
viral DNA inside the cell from various days postinfection were
quantitated by real-time Taqman PCR using E4-specific
primers. Even though infection with the three viruses was
executed at the same multiplicity of infection based on
infectious titer, the control Ad-wt-E3-EGFP virus showed
significantly lower total viral DNA synthesis and encapsidation
by about one order of magnitude compared to Ad-wt-E3-V-
EGFP and Ad-wt-E3-preVII-EGFP. By day 4, however, bothFig. 7. DNA packaging efficiency and cytopathic effect of core-labeled viruses. (A)
(--○--), Ad-wt-E3-V-EGFP (–△–), and Ad-wt-E3-preVII-EGFP (–□–). Each day, h
were processed for encapsidated viral DNA. Both viral DNA pools were quantitated b
panel shows the percent of encapsidated viral DNA for each respective virus (encapsi
the same three viruses was analyzed in 911 cells over the course of 10 days using
quantitated by MTS assay. Cell viability is expressed as percentage relative to noninfe
wt-E3-preVII-EGFP (–□–).the total intracellular viral genome copy number and the amount
of encapsidated viral DNA were nearly the same for all three
viruses, indicating that the growth kinetics of the control virus
may have been delayed (Fig. 6A, left and middle panels).
Expressing the data as encapsidation percentage of total viral
DNA further illustrates the stunted dynamics and essentially
lower yield of Ad-wt-E3-EGFP while concomitantly showing
equivalent behavior of Ad-wt-E3-V-EGFP and Ad-wt-E3-
preVII-EGFP (Fig. 7A, right panel).
Cytopathic effect of core-labeled viruses
To further evaluate the overall function of the core-labeled
viruses, cytopathic effect was assessed in comparison to the
control virus Ad-wt-E3-EGFP. 911 cells were infected with
various amounts of each virus (0.5, 0.05, and 0.005 CPEU/cell),
and their viability was assayed over the course of 10 days
postinfection. The cytopathic effect was not appreciably
different between the three viruses even at the lowest
multiplicity of infection (Fig. 7B).
Thermostability of core-labeled virions
We tested the thermostability of the viruses by exposing
equal amounts (based on t.u., transduction unit titer) of Ad-wt-
E3-EGFP, Ad-wt-E3-V-EGFP, and Ad-wt-E3-preVII-EGFP to
45 °C for various time periods. Following heat treatment, the
samples were functionally titered in terms of transduction
units. The thermostabilities of the core-labeled virions911 cells were infected over the course of 4 days with control Ad-wt-E3-EGFP
alf of the cells collected were processed for total viral DNAwhile the other half
y Taqman real-time quantitative PCR using E4-specific primers (n = 3). The third
dated divided by total and then multiplied by 100%). (B) The cytopathic effect of
the indicated multiplicities of infection. Every 2 days, the cell viability was
cted cells (n = 5). Ad-wt-E3-EGFP (--○--), Ad-wt-E3-V-EGFP (–△–), and Ad-
Fig. 8. Thermostability of core-labeled viruses. Ad-wt-E3-EGFP (white), Ad-
wt-V-EGFP (black), and Ad-wt-E3-preVII-EGFP (striped) were incubated at
45 °C for various times and then quantitated by transduction unit titer. Bars
represent percent of remaining infectivity relative to untreated samples (n = 3).
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of the control Ad-wt-E3-EGFP (Fig. 8).
Discussion
We have described herein successful labeling of the
adenovirus core through the chimeric expression of fluorescent
fusion core proteins V-EGFP and preVII-EGFP from the deleted
E3 region. Because of their nonutility for gene therapy
objectives and perhaps their indispensable role in formation of
the virus core, modification of core proteins has not been
exploited in recombinant adenoviruses. Such basis directed us
to pursue a conservative approach in labeling the adenovirus
core with a chimeric expression system wherein both the
fluorescent fusion core proteins and their native counterparts are
expressed from the same vector. This cautious strategy would
safeguard against unpredictable compromise of core protein
function due to the EGFP fusion.
In using a chimeric expression system, however, the relative
expression levels of the exogenous and endogenous core
proteins must be considered in light of the fact that each is
competing with the other for assembly into virions. As well, any
possibility of perturbing the structural function of the original
protein through the addition of EGFP should be taken into
account. Indeed, the former predicament was encountered when
applying our initial method of CMV-promoter-driven expression
from the deleted E1 region. The CMV promoter has been widely
used as a constitutive promoter to drive strong transgene
expression from nonreplicative adenoviral vectors. Neverthe-
less, adenoviral gene expression regulatory mechanisms during
replication pose a great challenge when using the foreign CMV
promoter to match the expression level of the endogenous core
proteins. Late in infection, adenoviral mRNA transcripts
containing the spliced 5′ tripartite leader sequence are
preferentially translated over transcripts lacking this element
(Berkner and Sharp, 1985; Chow et al., 1977; Logan and Shenk,1984). Transcripts generated from the CMV promoter would not
contain this tripartite leader sequence and would therefore be
translated at a lower level than the endogenous adenoviral L2
transcript from which the core proteins are made.
The tripartite leader sequence has been exploited to enhance
transgene expression from plasmid vectors by mating the
tripartite leader sequence downstream of certain nonadenoviral
promoters (Sheay et al., 1993). Moreover, a similar strategy was
employed in stable packaging cell lines to achieve strong
expression of a recombinant fiber protein in the context of
adenovirus replication (Von Seggern et al., 2000). We pursued
this approach to increase expression of the fusion core proteins
from the deleted E1 region. When applying the modified CMV5
promoter which contains the tripartite leader sequence to
improve transgene expression, we could only rescue Ad-E1-
CMV5-EGFP and Ad-E1-CMV5-V-EGFP. Past studies have
shown that pVII can interfere with adenovirus DNA synthesis
(Korn and Horwitz, 1986) and mRNA transcription in vitro
(Nakanishi et al., 1986). Protein Mu has the ability to precipitate
negatively charged DNA in vitro and plays a role in viral DNA
condensation in the core (Anderson et al., 1989). On this basis,
the untimely and strong expression of Mu-EGFP, preVII-EGFP,
and matVII-EGFP via the CMV5 promoter may explain the
failure to rescue these respective vectors. However, all E1-CMV
vectors were rescued, and yet increased gene expression of pV-
EGFP with CMV5 relative to CMV was not observed under our
experimental conditions. Unlike the E1-CMV5 approach, the
use of the deleted E3 region to express our transgenes was more
fruitful in that most viruses could be rescued (Ad-wt-E3-EGFP,
Ad-wt-E3-Mu-EGFP, Ad-wt-E3-V-EGFP, and Ad-wt-E3-pre-
VII-EGFP) except Ad-wt-E3-matVII-EGFP. Timely expression
in infection from the deleted E3 region (mostly via the major
late promoter) may explain these results.
Strong expression of the fusions pV-EGFP and preVII-EGFP
from the deleted E3 region yielded fluorescent virions under
fluorescence microscopy. It should be noted that Ad-wt-E3-V-
EGFP and Ad-wt-E3-preVII-EGFP particles showed qualita-
tively less intense and more heterogenous fluorescence than our
capsid-labeled Ad-IX-EGFP vector (Le et al., 2004). The weak
fluorescence seems paradoxical in the case of Ad-wt-E3-
preVII-EGFP since the copy number per virion of pVII is over
800 (Lehmberg et al., 1999), whereas the copy number per
virion of pIX is 240 (Lehmberg et al., 1999; van Oostrum and
Burnett, 1985). The nature of core labeling may compact the
fluorescent fusion core proteins within the capsid in close
proximity to each other, possibly diminishing the fluorescent
signal (e.g., through fluorescence energy transfer). On the other
hand, the labeling of the capsid with surface-exposed pIX-
EGFP would less likely result in this phenomenon. Addition-
ally, our capsid labeling strategy was based on complete
replacement of the IX gene with IX-EGFP, whereas core
labeling with preVII-EGFP also involved packaging of the non-
labeled, competing native pVII.
We were able to demonstrate the utility of our core-labeled
vectors by using their fluorescent property to monitor early
infection. Both Ad-wt-E3-V-EGFP and Ad-wt-E3-preVII-
EGFP fluorescent particles could be detected in the cytoplasm
299L.P. Le et al. / Virology 351 (2006) 291–302and nuclei of infected cells, indicating that the core-labeled
fluorescent virions were indeed infectious particles and not
merely protein conglomerates. The fluorescent signal was
detectable for both vectors during trafficking to the nucleus as
well as after nuclear translocation. While in the cytoplasm, these
fluorescent particles are likely the viral cores which remain
inside a partially dismantled capsid following cell entry (Greber
et al., 1993). After nuclear import, the fluorescent particles are
likely the delivered genome-containing viral cores released
from the capsid (Greber et al., 1997). Interestingly, the punctate
fluorescence of Ad-wt-E3-preVII-EGFP was maintained in the
nucleus longer than that of Ad-wt-E3-V-EGFP. This observa-
tion suggests that pV-EGFP may dissociate from the delivered
viral core earlier than pVII-EGFP. A previous report has shown
that protein VII remains with the input viral genome throughout
the early phase of infection (Xue et al., 2005). Our data with Ad-
wt-E3-preVII-EGFP corroborate this observation at least up to
3 h postinfection. One drawback of our core-labeled vectors is
the fact that, at 6 h postinfection, strong de novo expression of
the fusion core proteins from the delivered genomes prevented
detection of the input fluorescent viral core. Although strong
expression from the E3 region is attributed to the major late
promoter (Mittal et al., 1993), the upstream E3 enhancer/
promoter may induce expression of transgenes in this region
earlier in infection. Because optimal E3 promoter activity is
dependent on E1A expression (Berk, 1986), future studies
employing E1-deleted core-labeled vectors may prevent early
expression of the fusion core proteins to allow tracking of the
input fluorescent viral cores at 6 h postinfection and perhaps
even later.
Various assays were performed to evaluate the viability of
the core-labeled vectors Ad-wt-E3-V-EGFP and Ad-wt-E3-
preVII-EGFP. In the DNA packaging analysis, the viral DNA
replication and encapsidation of the control Ad-wt-E3-EGFP
were poor compared to the two core-labeled viruses (about one
order lower) despite using the same multiplicity of infection for
all three vectors. Interestingly, the only difference between the
control virus and the other two vectors is expression of diffusely
localizing EGFP for the former versus expression of nuclear
localizing fusion core proteins with EGFP for the latter two. It is
difficult to attribute increased DNA replication to the over-
expression of the core proteins (i.e., native pV plus modified V-
EGFP, Fig. 3B, right panel, lane 4) in the case of Ad-wt-E3-V-
EGFP and Ad-wt-E3-preVII-EGFP since high expression of
these proteins occurs late after DNA replication. On the other
hand, it is plausible that the increased presence of the core
proteins may lead to increased packaging efficiency late in
infection resulting in a higher readout using our assay. It is also
likely that the high expression of EGFP by itself may influence
the kinetics of viral replication through its interactions with viral
proteins or the host cell. In this respect, EGFP has been reported
to cause toxicity both in living cells and in mice (Huang et al.,
2000; Liu et al., 1999). We did note in the tracking experiment
that EGFP was expressed much earlier and stronger (at 3 h
postinfection) in most cells infected with the control Ad-wt-E3-
EGFP vector relative to fusion core protein expression from Ad-
wt-E3-V-EGFP and Ad-wt-E3-preVII-EGFP.Another anomaly between control Ad-wt-E3-EGFP and the
core-labeled vectors was discovered in the thermostability
assay. Both modified viruses appeared more thermostable than
the control. Following exposure of the viruses to 45 °C,
transduction unit titer was used as an infectious index of viral
function. Because the control virus was practically wild-type
with respect to its capsid and core structure, the incorporation of
the fusion core proteins into the modified viruses may have
imparted additional stability. Whether the increased thermosta-
bility pertains to the entire adenovirus structure or just the core
is uncertain. It is possible that a more thermostable core alone
would produce the results we obtained since a DNA–pVII
complex by itself has transfection capability (Wienhues et al.,
1987). Such “nonviral” transduction capability would likely
contribute to the increased t.u. titers we measured for the core-
labeled vectors.
In summary, we have demonstrated the fluorescent labeling
of the adenovirus core by competitive expression of fusions pV-
EGFP and preVII-EGFP from the deleted E3 region. Strong
expression of these fusion core proteins from the E3 region did
not negatively impact DNA replication, DNA encapsidation,
thermostability, and cytopathic effect of the viruses. The
purified particles were labeled and fluorescent, allowing their
detection under fluorescence microscopy. A future extension of
the techniques described here is to generate recombinant
adenoviruses with complete replacement of the native V or
preVII gene with the fusion V-EGFP or preVII-EGFP. Core
labeling of adenoviruses would allow the tracking of the
adenovirus core and complements our capsid labeling technique




Human embryonic retinoblast 911 (Fallaux et al., 1996),
human lung adenocarcinoma A549 (American Type Culture
Collection (ATCC), Manassas, VA), human cervical carcinoma
HeLa (ATCC), and Chinese hamster ovary (CHO, ATCC) cells
were maintained according to the suppliers' protocols. Cells
were incubated at 37 °C and 5% CO2 under humidified
conditions.
Recombinant adenovirus construction
All viruses were constructed by homologous recombination
in Escherichia coli (He et al., 1998). The base plasmids were
acquired from the following sources: pShuttle-CMV, pAdeno-
Vator-CMV5, and pAdEasy (Qbiogene, Irvine, CA); pcDNA3-
CMV-V-EGFP (Matthews, 2001), pcDNA3-CMV-Mu-EGFP
(Lee et al., 2004), pcDNA3-CMV-preVII-EGFP (Lee et al.,
2003), pcDNA3-CMV-matVII-EGFP (Lee et al., 2003); shuttle
plasmids for the E1-CMV/E3-deleted chimeric expression
vectors were constructed as follows using restriction cloning:
pShuttle-E1-CMV-V-EGFP → pShuttle-CMV/SalI/blunt/
KpnI + pcDNA3-CMV-V-EGFP/ApaI/blunt/KpnI; pShuttle-
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KpnI + pcDNA3-CMV-Mu-EGFP/ApaI/blunt/KpnI; pShuttle-
E1-CMV-preVI I -EGFP → pShut t l e -CMV/EcoRV/
KpnI + pcDNA3-CMV-preVII-EGFP/ApaI/blunt/KpnI; pShut-
tle-E1-CMV-matVII-EGFP → pShuttle-CMV/EcoRV/
KpnI + pcDNA3-CMV-matVII-EGFP/ApaI/blunt/KpnI. pShut-
tle-E1-CMV-EGFP was cloned in two steps. pcDNA3-CMV-V-
EGFP was cut with BamHI and self-ligated to remove the V
fusion. Then, the resulting plasmid was cut with ApaI/blunt/
KpnI to liberate the EGFP gene for ligation into pShuttle-CMV
cut with EcoRV/KpnI.
Shuttle plasmids for vectors expressing the fusion core
proteins under the modified CMV5 promoter (containing the
adenovirus tripartite leader sequence) were constructed with
pAdenoVator-CMV5. For EGFP, Mu-EGFP, preVII-EGFP, and
matVII-EGFP, the respective pShuttle-E1-CMV plasmids con-
taining these genes as described above were cut with BglII/
BstXI to release the transgene and a portion of the right
homologous arm. These fragments were ligated into pAdeno-
Vator-CMV5 cut with BamHI/BstXI (fragment which contains
the CMV5 promoter). To generate pAdenoVator-CMV5-V-
EGFP, pShuttle-E1-CMV-V-EGFP was cut with SalI/blunt/
BstXI to give a fragment with the fusion gene and then ligated
into pAdenoVator cut with PmeI/BstXI.
Finally, a parent E3 shuttle plasmid was made to insert the
same fusion genes into the adenovirus E3 region by double
selection homologous recombination. Briefly, pShuttlE3
contains the left and right homologous arms from pBHG10
(Microbix, Toronto, CA) flanking the E3-deleted region
which has been replaced by a unique PacI site. The
kanamycin gene along with the multiple cloning site from
pABS.4 (Microbix) was cloned into the unique PacI site,
eliminating it in the process, to make the final pShuttlE3.
Detailed steps will be provided upon request. pShuttlE3-V-
EGFP was constructed by first subcloning the KpnI/SphI V-
EGFP cut from pcDNA3-CMV-V-EGFP into pABS.4 also cut
with the same enzymes. An SphI/XhoI partial digest was
performed on the resulting plasmid to move the V-EGFP gene
into the corresponding restriction sites in pShuttlE3. All of the
other pShuttlE3 plasmids were made by cutting the respective
fusion core genes out of the pShuttle-E1-CMV vectors
described above with BglII/HpaI and then inserting it into
pShuttlE3 cut with SalI/blunt/BglII. All blunted fragments
were generated with the large Klenow fragment (New
England Biolabs, Beverly, MA). The plasmids were verified
by restriction cutting. All E1 shuttle plasmids were recom-
bined with the pAdEasy rescue plasmid in BJ5183 cells,
whereas the E3 shuttle plasmids were recombined with the
pTG3602 rescue backbone. Since the pShuttlE3 plasmids
contain the kanamycin gene and the fusion core gene flanked
by the homologous arms, recombination was performed using
double selection for ampicillin from the rescue plasmid
pTG3602 and kanamycin from pShuttlE3. Subsequently,
kanamycin was cut out of the genomes with the two
surrounding SwaI sites. After self-ligation, the final adenovi-
ral genomes were linearized with PacI and then transiently
transfected into 911 cells.Virus propagation and purification
Viruses were propagated in 911 cells and purified by double
cesium chloride (CsCl) ultracentrifugation followed by dialysis
against phosphate-buffered saline with Mg2+, Ca2+, and 10%
glycerol. Final aliquots of virus were analyzed for viral particle
titer (absorbance at 260 nm) and transduction unit (t.u.) titer.
Based on a previously described protocol (Alemany et al.,
2000), t.u. was determined by infecting 15,000 911 cells in 96-
well plates with 1:10 serial dilutions of the virus and counting
the number of green cells 2 days postinfection (n = 6). In
addition, all viruses were quantitated for cytopathic effect unit
(CPEU) titer. 911 cells in 96-well plates (15,000 per well) were
infected with 1:10 serial dilutions of the virus. Two days
postinfection, cell viability was determined with an MTS assay
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium; Promega, Madison, WI). The
TCID50 dose was determined and back-calculated to obtain the
CPEU titer where theoretically 1 CPEU kills one cell in 2 days.
All viruses were stored at −80 °C until use.
Fluorescence microscopy
A549 cells seeded on glass coverslips were transduced with
100 viral particles per cell of Ad-E1-CMV-EGFP, Ad-E1-CMV-
Mu-EGFP, Ad-E1-CMV-V-EGFP, Ad-E1-CMV-preVII-EGFP,
and Ad-E1-CMV-matVII-EGFP. Twenty-four hours postinfec-
tion, the cells were washed with PBS, fixed, stained with
Hoechst 33342 (Molecular Probes, Eugene, OR), and mounted
on glass slides (Fisher Scientific, Pittsburgh, PA). Epifluores-
cence microscopy was performed with an inverted IX-70
microscope (Olympus, Melville, NY) equipped with a Magni-
fire digital CCD camera (Optronics, Goleta, CA). Images were
acquired with a 100× objective using oil immersion and
digitally deconvoluted with Iris, version 4.15a (http://www.
astrosurf.com/buil/) by applying the Richardson-Lucy algo-
rithm with 15 iterations. An image of a single fluorescent Ad-
IX-EGFP (Le et al., 2004) virus particle with strong signal-to-
noise ratio was used to determine the point spread function as
suggested by the software documentation. EGFP and Hoechst
stain images were merged using Adobe Photoshop 7.0 (San
Jose, CA).
Western blot
Top and bottom band samples of purified control Ad-E1-
CMV-EGFP and Ad-E1-CMV-V-EGFP (8 μg) were resolved
with SDS-PAGE and then transferred to a polyvinylidene
difluoride membrane (BioRad, Hercules, CA). Blotting was
performed with a primary monoclonal GFP antibody (1:1000
dilution, BD Biosciences Clontech) followed by a secondary
HRP-linked anti-mouse antibody (1:5000 dilution, Amersham
Pharmacia, Piscataway, NJ) or a primary polyclonal pV
antibody (1:1000 dilution, Chemicon International, Inc.,
Temecula, CA) followed by a secondary HRP-linked anti-
rabbit antibody (1:5000 dilution, Dako, Carpinteria, CA). Bands
were detected with a chemiluminescent ECL kit (Amersham
301L.P. Le et al. / Virology 351 (2006) 291–302Pharmacia, Piscataway, NJ). For analysis of protein expression
from the V-EGFP vectors, 2 × 105 911 cells were infected with 1
CPEU/cell of Ad-E1-CMV-EGFP, Ad-E1-CMV-V-EGFP, Ad-
E1-CMV5-V-EGFP, and Ad-wt-E3-V-EGFP in 12-well plates.
Twenty-four hours postinfection, the cells were collected and
lysed with RIPA buffer (100 μL). Samples (10 μg) were
subjected to SDS-PAGE and blotting with GFP and pV
antibodies as described above. Purified Ad-wt-E3-EGFP, Ad-
wt-E3-V-EGFP, and Ad-wt-E3-preVII-EGFP (1.5 × 1010 vp of
each virus in RIPA buffer) were also subjected to 15% SDS-
PAGE for silver staining (Silver Stain Plus, BioRad, Hercules,
CA).
Characterization of virus gradient fractions
For the fractionation studies, viruses were propagated each in
ten 150-mm dishes of 911 cells. Collected crude viral lysates
were purified by CsCl ultracentrifugation where the top and
bottom bands were retained through two centrifugation steps
yielding one gradient from the 10 dishes. After the second spin,
fractions (∼100 μL) were collected dropwise through a
perforation at the bottom of the tube into 96-well white opaque
plates. Plates with the viral fractions were measured with a
microplate fluorometer (Fluostar Optima, BMG Labtechnolo-
gies, Durham, NC) using 490/10 nm excitation and 510/10 nm
emission filters. To determine viral DNA content, a sample of
each fraction (10 μL) was diluted in 90 μL 0.5% SDS/PBS and
incubated at room temperature for 10 min to release the viral
genomes. Absorbance at 260 nm was then measured for each
sample (MBA 2000, Perkin Elmer, Shelton, CT).
Visualization of purified core-labeled viruses
Diluted, purified Ad-wt-E3-V-EGFP, and Ad-wt-E3-preVII-
EGFP viral particles (1:100 in PBS) were prepared on glass
slides with coverslips and then sealed for fluorescence imaging
as described above.
Tracking assay
HeLa cells (1 × 105 cells per dish) were seeded in 50/30 mm
glass bottom dishes (Willco Wells B.V., Amsterdam, The
Netherlands). The next day, the cells were stained for DNAwith
Hoechst 33342 (Molecular Probes, Eugene, OR) in normal
growth medium and then washed three times with PBS. The
cells were then infected with Ad-wt-E3-EGFP, Ad-wt-E3-V-
EGFP, and Ad-wt-E3-preVII-EGFP (100,000 viral particles per
cell) in 300 μL of normal growth medium at 37 °C and under
humidified conditions. Three dishes were prepared for each
virus. After 1 h of infection, the dishes were washed with PBS
three times to remove free virus. One of three dishes for each
virus was imaged under fluorescence microscopy (described
above) with PBS in the dish and noted as time point 1 h
postinfection. The remaining two dishes for each virus were
reincubated with growth medium (700 μL) at 37 °C. At 3 h
after infection, a second dish for each virus was washed with
PBS three times and then likewise imaged with the cells in PBS.The last dish was imaged as time point 6 h postinfection. Note
that the timing of infection started with addition of virus to the
cells. Acquired images were digitally deconvoluted as described
above.
DNA packaging analysis
DNA packaging was analyzed by using a previously
reported protocol (Yamamoto et al., 2003). Briefly, 911 cells
(5 × 104) were infected with Ad-wt-E3-EGFP, Ad-wt-E3-V-
EGFP, and Ad-wt-E3-preVII-EGFP with 1 CPEU/cell in 12-
well plates. On days 1, 2, 3, and 4 postinfection, the cells were
collected. One half of the cell pellet was processed for total viral
genome copy number, and the other half was processed for
encapsidated viral genome copy number (QIAamp DNA Blood
Mini Kit, QIAGEN, Valencia, CA). The viral DNA pools were
quantitated with Taqman quantitative real-time PCR using E4-
specific primers (LightCycler System, Roche Applied Science,
Indianapolis, IN).
Cytopathic effect assay
Five thousand 911 cells were infected with Ad-wt-E3-EGFP,
Ad-wt-E3-V-EGFP, and Ad-wt-E3-preVII-EGFP (0.5 CPEU/
cell, 0.05 CPEU/cell, and 0.005 CPEU/cell of each vector) in
100 μL of 5% DME medium without phenol red (five replicates
for each condition plus five noninfected wells as controls).
Cytopathic effect was measured by an MTS assay (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium; Promega, Madison, WI) on days 0, 2,
4, 6, 8, and 10 postinfection. Results were calculated as viability
percent of noninfected cells with blank values (medium only)
subtracted beforehand.
Thermostability assay
Thermostability was analyzed using a modified version of a
previously reported protocol (Dmitriev et al., 2002). Samples of
Ad-CMV-EGFP and Ad-IX-EGFP (106 t.u. in 100 μL PBS)
were incubated for various time periods at 45 °C (0, 5, 10, 20,
and 40 min). Transduction unit infectious titers were then
determined for the samples using the abovementioned protocol.
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